Targeting 2A Protease by RNA Interference Attenuates Coxsackieviral Cytopathogenicity and Promotes Survival in Highly Susceptible Mice
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Background— Enteroviridae such as coxsackievirus B3 (CVB3) are important infectious agents involved in viral heart disease, hepatitis, and pancreatitis, but no specific antiviral therapy is available. Methods and Results— The aim of the present study was to evaluate the impact of RNA interference on viral replication, cytopathogenicity, and survival. Small interfering RNA (siRNA) molecules were designed against the viral 2A region (siRNA-2A), which is considered to be highly conserved and essential for both virus maturation and host cytopathogenicity. siRNA-2A exhibited a significant protective effect on cell viability mediated by marked inhibition of CVB3 gene expression and viral replication. In highly susceptible type I interferon receptor–knockout mice, siRNA-2A led to significant reduction of viral tissue titers, attenuated tissue damage, and prolonged survival. Repeated siRNA-2A transfection was associated with a further improvement of survival. Various control siRNA molecules had no protective effect in vitro or in vivo. Conclusions— RNA interference directed against the 2A protease encoding genomic region effectively confers intracellular immunity toward CVB3-mediated cell injury and improves survival, suggesting a potential role for RNA interference for future treatment options targeting enteroviral diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kawamura, N., Kohara, M., Abe, S., Komatsu, T., Tago, K., Arita, M., & Nomoto, A. (1989) · Journal of Virology · doi:10.1128/jvi.63.3.1302-1309.1989 · Cited by 232
Cited by
Progress towards in Vivo Use of siRNAs
Behlke, M. A. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.01.001 · Cited by 677
“VB3 Mouse—virus IV–hydrodynamic No No [159] 2005 est Nile virus Mouse—virus IV–hydrodynamic No No [158] 2005 TABLE 1 (continued) REVIEW ARTICLE doi:10.”
BackgroundThe silent treatment: siRNAs as small molecule drugs
Dykxhoorn, D. M., Palliser, D., & Lieberman, J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302703 · Cited by 324
Host and virus determinants of picornavirus pathogenesis and tropism
Whitton, J. L., Cornell, C. T., & Feuer, R. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1284 · Cited by 252
Fechner, H., Sipo, I., Westermann, D., Pinkert, S., Wang, X., Suckau, L., Kurreck, J., Zeichhardt, H., Müller, O., Vetter, R., et al. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0363-x · Cited by 79
“In one of these [9] chemically synthesised siRNA and in the other [10] plasmids transcribing shRNA were applied by rapid high-volume intravenous injection in mice.”
BackgroundMethodExploiting the Therapeutic Potential of MicroRNAs in Viral Diseases: Expectations and Limitations
Hemida, M. G., Ye, X., Thair, S., & Yang, D. (2010) · Molecular Diagnosis & Therapy · doi:10.1007/bf03256383 · Cited by 32
Metadata
- Authors
- Merl, S., Michaelis, C., Jaschke, B., Vorpahl, M., Seidl, S., & Wessely, R.
- Venue
- Circulation
- Published
- 2005-04-05
- Volume
- 111
- Issue
- 13
- Pages
- 1583-1592
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1995409972
- Cited by
- 67
- References
- 1
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting 2A Protease by RNA Interference Attenuates Coxsackieviral Cytopathogenicity and Promotes Survival in Highly Susceptible Mice. https://app.cochat.ai/papers/10.1161/01.cir.0000160360.02040.ab
- The paper
- Merl, S., Michaelis, C., Jaschke, B., Vorpahl, M., Seidl, S., & Wessely, R. (2005). Targeting 2A Protease by RNA Interference Attenuates Coxsackieviral Cytopathogenicity and Promotes Survival in Highly Susceptible Mice. Circulation. https://doi.org/10.1161/01.cir.0000160360.02040.ab
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.